# US 12,178,853 B2 · Method and compounds for treating diabetes and associated metabolic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,853 B2
- Document ID: US12178853B2
- Status: Granted
- Kind: B2
- Application number: 17/499,296
- Filed: 2021-10-12
- Published: 2022-04-14
- Granted: 2024-12-31
- Earliest claimed: 2020-10-13
- Assignees: Betavive Ltd.
- Applicants: Betavive Ltd.
- Inventors: Yoram Palti; Dotan Zuri
- Web page: https://patentgrep.com/patent/US12178853B2

## CPC

- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering first, second, third, fourth, and fifth daily doses of insulin-like growth factor 2 (“IGF-2”) or a variant thereof to the subject at respective first, second, third, fourth, and fifth different times, wherein each of the daily doses comprises at least 65 μg of IGF-2. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.

## Claims

### Claim 1

A method of treating Type 1 or Type 2 diabetes in a subject in need of treatment, the subject having a weight, the method comprising: administering first, second, third, fourth, and fifth daily doses of insulin like growth factor 2 (IGF-2) to the subject at respective first, second, third, fourth, and fifth different days, wherein each of the daily doses comprises 65 μg to 1626 μg of IGF-2 thereof per kg of the weight.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first, second, third, fourth, and fifth different days occur on consecutive days.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering sixth, seventh, and eighth daily doses of IGF-2 to the subject at respective sixth, seventh, and eighth different days.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering sixth, seventh, eighth, ninth, and tenth daily doses of IGF-2 to the subject at respective sixth, seventh, eighth, ninth, and tenth different days, wherein the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth different days occur on consecutive days.

### Claim 5 (depends on 1)

The method of claim 1, wherein each of the daily doses comprises at least 163 μg of IGF-2 per kg of the weight.

### Claim 6 (depends on 1)

The method of claim 1, wherein each of the daily doses comprises at least 244 μg of IGF-2 per kg of the weight.

### Claim 7 (depends on 1)

The method of claims 1, wherein each of the daily doses comprises at least 813 μg of IGF-2 per kg of the weight.